mRNA vaccine development for cholangiocarcinoma: a precise pipeline

Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however,...

Full description

Saved in:
Bibliographic Details
Published in:Military medical research 2022-07, Vol.9 (1), p.40-40, Article 40
Main Authors: Tang, Tian-Yu, Huang, Xing, Zhang, Gang, Lu, Ming-Hao, Liang, Ting-Bo
Format: Article
Language:English
Subjects:
Antigens
Bile Duct Neoplasms
Bile Ducts, Intrahepatic
Bioinformatics
Cancer therapies
Cholangiocarcinoma
Cholangiocarcinoma (CHOL)
Gene expression
Genomes
Genomics
Growth factors
Humans
Immune microenvironment
Immune subtype
Immune system
Immunotherapy
Kinases
Medical prognosis
mRNA vaccine
mRNA Vaccines
Mutation
Peptides
Response rates
RNA, Messenger
Tumor antigen
Tumors
Vaccines, Synthetic
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c493t-4e475dc0dccc3ee5830fcc5bf33701e9d29a0090996149baeab495adde6196a3
cites cdi_FETCH-LOGICAL-c493t-4e475dc0dccc3ee5830fcc5bf33701e9d29a0090996149baeab495adde6196a3
container_end_page 40
container_issue 1
container_start_page 40
container_title Military medical research
container_volume 9
creator Tang, Tian-Yu
Huang, Xing
Zhang, Gang
Lu, Ming-Hao
Liang, Ting-Bo
description Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however, its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect, further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.
doi_str_mv 10.1186/s40779-022-00399-8
format article
fullrecord <record><control><sourceid>proquest_doaj_</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_fd2807895dfa4fc4a3f6786306c4107d</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_fd2807895dfa4fc4a3f6786306c4107d</doaj_id><sourcerecordid>2691305361</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-4e475dc0dccc3ee5830fcc5bf33701e9d29a0090996149baeab495adde6196a3</originalsourceid><addsrcrecordid>eNpdkU1r3DAQhk1paUKaP9BDMfTSi9vRhyVND4Ww9CMQWii5C6003mixLVfaXci_r5JNQ9KThPTMw8y8TfOWwUfGjPpUJGiNHXDeAQjEzrxoTjn0skOh8OWT-0lzXsoWAJiQnCF_3ZyI3nAGSp82q-n3z4v24LyPM7WBDjSmZaJ51w4pt_4mjW7exORdrkCa3OfWtUsmHwu1S1xorGVvmleDGwudP5xnzfW3r9erH93Vr--Xq4urzksUu06S1H3wELz3gqg3Agbv-_UghAZGGDg6AARExSSuHbm1xN6FQIqhcuKsuTxqQ3Jbu-Q4uXxrk4v2_iHljXV5F_1IdgjcgDbYh8HJwUsnBqWNEqC8ZKBDdX05upb9eqLg68DZjc-kz3_meGM36WCRa224qYIPD4Kc_uyp7OwUi6exrovSvliuDIICwXhF3_-HbtM-z3VTlUImoBeKVYofKZ9TKZmGx2YY2LvE7TFxWxO394nbuy7ePR3jseRfvuIvIh-mhQ</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2691305361</pqid></control><display><type>article</type><title>mRNA vaccine development for cholangiocarcinoma: a precise pipeline</title><source>Open Access: PubMed Central</source><source>Publicly Available Content Database</source><creator>Tang, Tian-Yu ; Huang, Xing ; Zhang, Gang ; Lu, Ming-Hao ; Liang, Ting-Bo</creator><creatorcontrib>Tang, Tian-Yu ; Huang, Xing ; Zhang, Gang ; Lu, Ming-Hao ; Liang, Ting-Bo</creatorcontrib><description>Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however, its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect, further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.</description><identifier>ISSN: 2054-9369</identifier><identifier>ISSN: 2095-7467</identifier><identifier>EISSN: 2054-9369</identifier><identifier>DOI: 10.1186/s40779-022-00399-8</identifier><identifier>PMID: 35821067</identifier><language>eng</language><publisher>England: BioMed Central</publisher><subject>Antigens ; Bile Duct Neoplasms ; Bile Ducts, Intrahepatic ; Bioinformatics ; Cancer therapies ; Cholangiocarcinoma ; Cholangiocarcinoma (CHOL) ; Gene expression ; Genomes ; Genomics ; Growth factors ; Humans ; Immune microenvironment ; Immune subtype ; Immune system ; Immunotherapy ; Kinases ; Medical prognosis ; mRNA vaccine ; mRNA Vaccines ; Mutation ; Peptides ; Response rates ; RNA, Messenger ; Tumor antigen ; Tumors ; Vaccines, Synthetic</subject><ispartof>Military medical research, 2022-07, Vol.9 (1), p.40-40, Article 40</ispartof><rights>2022. The Author(s).</rights><rights>2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-4e475dc0dccc3ee5830fcc5bf33701e9d29a0090996149baeab495adde6196a3</citedby><cites>FETCH-LOGICAL-c493t-4e475dc0dccc3ee5830fcc5bf33701e9d29a0090996149baeab495adde6196a3</cites><orcidid>0000-0002-8886-2777</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277828/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2691305361?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,25731,27901,27902,36989,36990,44566,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35821067$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tang, Tian-Yu</creatorcontrib><creatorcontrib>Huang, Xing</creatorcontrib><creatorcontrib>Zhang, Gang</creatorcontrib><creatorcontrib>Lu, Ming-Hao</creatorcontrib><creatorcontrib>Liang, Ting-Bo</creatorcontrib><title>mRNA vaccine development for cholangiocarcinoma: a precise pipeline</title><title>Military medical research</title><addtitle>Mil Med Res</addtitle><description>Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however, its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect, further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.</description><subject>Antigens</subject><subject>Bile Duct Neoplasms</subject><subject>Bile Ducts, Intrahepatic</subject><subject>Bioinformatics</subject><subject>Cancer therapies</subject><subject>Cholangiocarcinoma</subject><subject>Cholangiocarcinoma (CHOL)</subject><subject>Gene expression</subject><subject>Genomes</subject><subject>Genomics</subject><subject>Growth factors</subject><subject>Humans</subject><subject>Immune microenvironment</subject><subject>Immune subtype</subject><subject>Immune system</subject><subject>Immunotherapy</subject><subject>Kinases</subject><subject>Medical prognosis</subject><subject>mRNA vaccine</subject><subject>mRNA Vaccines</subject><subject>Mutation</subject><subject>Peptides</subject><subject>Response rates</subject><subject>RNA, Messenger</subject><subject>Tumor antigen</subject><subject>Tumors</subject><subject>Vaccines, Synthetic</subject><issn>2054-9369</issn><issn>2095-7467</issn><issn>2054-9369</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNpdkU1r3DAQhk1paUKaP9BDMfTSi9vRhyVND4Ww9CMQWii5C6003mixLVfaXci_r5JNQ9KThPTMw8y8TfOWwUfGjPpUJGiNHXDeAQjEzrxoTjn0skOh8OWT-0lzXsoWAJiQnCF_3ZyI3nAGSp82q-n3z4v24LyPM7WBDjSmZaJ51w4pt_4mjW7exORdrkCa3OfWtUsmHwu1S1xorGVvmleDGwudP5xnzfW3r9erH93Vr--Xq4urzksUu06S1H3wELz3gqg3Agbv-_UghAZGGDg6AARExSSuHbm1xN6FQIqhcuKsuTxqQ3Jbu-Q4uXxrk4v2_iHljXV5F_1IdgjcgDbYh8HJwUsnBqWNEqC8ZKBDdX05upb9eqLg68DZjc-kz3_meGM36WCRa224qYIPD4Kc_uyp7OwUi6exrovSvliuDIICwXhF3_-HbtM-z3VTlUImoBeKVYofKZ9TKZmGx2YY2LvE7TFxWxO394nbuy7ePR3jseRfvuIvIh-mhQ</recordid><startdate>20220712</startdate><enddate>20220712</enddate><creator>Tang, Tian-Yu</creator><creator>Huang, Xing</creator><creator>Zhang, Gang</creator><creator>Lu, Ming-Hao</creator><creator>Liang, Ting-Bo</creator><general>BioMed Central</general><general>BMC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88F</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M1Q</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-8886-2777</orcidid></search><sort><creationdate>20220712</creationdate><title>mRNA vaccine development for cholangiocarcinoma: a precise pipeline</title><author>Tang, Tian-Yu ; Huang, Xing ; Zhang, Gang ; Lu, Ming-Hao ; Liang, Ting-Bo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-4e475dc0dccc3ee5830fcc5bf33701e9d29a0090996149baeab495adde6196a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antigens</topic><topic>Bile Duct Neoplasms</topic><topic>Bile Ducts, Intrahepatic</topic><topic>Bioinformatics</topic><topic>Cancer therapies</topic><topic>Cholangiocarcinoma</topic><topic>Cholangiocarcinoma (CHOL)</topic><topic>Gene expression</topic><topic>Genomes</topic><topic>Genomics</topic><topic>Growth factors</topic><topic>Humans</topic><topic>Immune microenvironment</topic><topic>Immune subtype</topic><topic>Immune system</topic><topic>Immunotherapy</topic><topic>Kinases</topic><topic>Medical prognosis</topic><topic>mRNA vaccine</topic><topic>mRNA Vaccines</topic><topic>Mutation</topic><topic>Peptides</topic><topic>Response rates</topic><topic>RNA, Messenger</topic><topic>Tumor antigen</topic><topic>Tumors</topic><topic>Vaccines, Synthetic</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tang, Tian-Yu</creatorcontrib><creatorcontrib>Huang, Xing</creatorcontrib><creatorcontrib>Zhang, Gang</creatorcontrib><creatorcontrib>Lu, Ming-Hao</creatorcontrib><creatorcontrib>Liang, Ting-Bo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Military Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Military Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Military medical research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tang, Tian-Yu</au><au>Huang, Xing</au><au>Zhang, Gang</au><au>Lu, Ming-Hao</au><au>Liang, Ting-Bo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>mRNA vaccine development for cholangiocarcinoma: a precise pipeline</atitle><jtitle>Military medical research</jtitle><addtitle>Mil Med Res</addtitle><date>2022-07-12</date><risdate>2022</risdate><volume>9</volume><issue>1</issue><spage>40</spage><epage>40</epage><pages>40-40</pages><artnum>40</artnum><issn>2054-9369</issn><issn>2095-7467</issn><eissn>2054-9369</eissn><abstract>Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however, its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect, further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.</abstract><cop>England</cop><pub>BioMed Central</pub><pmid>35821067</pmid><doi>10.1186/s40779-022-00399-8</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-8886-2777</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2054-9369
ispartof Military medical research, 2022-07, Vol.9 (1), p.40-40, Article 40
issn 2054-9369
2095-7467
2054-9369
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_fd2807895dfa4fc4a3f6786306c4107d
source Open Access: PubMed Central; Publicly Available Content Database
subjects Antigens
Bile Duct Neoplasms
Bile Ducts, Intrahepatic
Bioinformatics
Cancer therapies
Cholangiocarcinoma
Cholangiocarcinoma (CHOL)
Gene expression
Genomes
Genomics
Growth factors
Humans
Immune microenvironment
Immune subtype
Immune system
Immunotherapy
Kinases
Medical prognosis
mRNA vaccine
mRNA Vaccines
Mutation
Peptides
Response rates
RNA, Messenger
Tumor antigen
Tumors
Vaccines, Synthetic
title mRNA vaccine development for cholangiocarcinoma: a precise pipeline
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-29T08%3A07%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_doaj_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=mRNA%20vaccine%20development%20for%20cholangiocarcinoma:%20a%20precise%20pipeline&rft.jtitle=Military%20medical%20research&rft.au=Tang,%20Tian-Yu&rft.date=2022-07-12&rft.volume=9&rft.issue=1&rft.spage=40&rft.epage=40&rft.pages=40-40&rft.artnum=40&rft.issn=2054-9369&rft.eissn=2054-9369&rft_id=info:doi/10.1186/s40779-022-00399-8&rft_dat=%3Cproquest_doaj_%3E2691305361%3C/proquest_doaj_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c493t-4e475dc0dccc3ee5830fcc5bf33701e9d29a0090996149baeab495adde6196a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2691305361&rft_id=info:pmid/35821067&rfr_iscdi=true